FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1577654792> ?p ?o ?g. }

• W1577654792 endingPage "47" @default.
• W1577654792 startingPage "36" @default.
• W1577654792 abstract "Carmant L. Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing.Acta Neurol Scand: 2011: 124 (Suppl. 192): 36–47.© 2011 John Wiley & Sons A/S. Infantile spasms (IS) are a unique and severe form of epilepsy associated with poor neurologic and developmental outcomes. The refractory spasms and abnormal electroencephalogram (EEG) patterns associated with the condition are believed to have a progressively detrimental impact. Therefore, rapid and complete control of spasms is the primary goal of treatment. Well-controlled clinical trials in Europe, Canada, and the United States have demonstrated that vigabatrin is efficacious and generally well-tolerated as monotherapy for IS. Several key studies, including pivotal trials that led to United States approval of vigabatrin in 2009, as well as comparative trials of vigabatrin and hormonal treatment, are the focus of this review. All studies assessed spasm cessation — usually as the primary endpoint — and adverse events. Vigabatrin dosages generally ranging from 100 to 150 mg/kg/day demonstrated efficacy to decrease or eradicate spasms and eliminate hypsarrhythmic EEG in patients with newly diagnosed IS. Several studies demonstrated long-term sustainability of spasm freedom with no negative impact on developmental outcomes. Vigabatrin was generally well-tolerated with few severe adverse events. Visual field defects cannot be adequately assessed in infants and young children, so this potential adverse effect was not evaluated in children with spasms. Notably, the time to response with vigabatrin was very rapid, generally occurring within 2 weeks of initial treatment. This allows for early treatment modification as needed. For infants who respond well to vigabatrin, treatment duration up to 6 months appears to be appropriate for realizing spasm freedom while limiting potential risks of adverse events and recurrences." @default.
• W1577654792 created "2016-06-24" @default.
• W1577654792 creator A5058439594 @default.
• W1577654792 date "2011-11-08" @default.
• W1577654792 modified "2023-10-01" @default.
• W1577654792 title "Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing" @default.
• W1577654792 cites W1485263538 @default.
• W1577654792 cites W1487866431 @default.
• W1577654792 cites W1500704400 @default.
• W1577654792 cites W1512485978 @default.
• W1577654792 cites W1514107548 @default.
• W1577654792 cites W1601945518 @default.
• W1577654792 cites W1604045591 @default.
• W1577654792 cites W1762041142 @default.
• W1577654792 cites W1886767962 @default.
• W1577654792 cites W1966186739 @default.
• W1577654792 cites W1993874403 @default.
• W1577654792 cites W1997190808 @default.
• W1577654792 cites W20367449 @default.
• W1577654792 cites W2037122149 @default.
• W1577654792 cites W2049681451 @default.
• W1577654792 cites W2050910356 @default.
• W1577654792 cites W2058728136 @default.
• W1577654792 cites W2060406365 @default.
• W1577654792 cites W2069231742 @default.
• W1577654792 cites W2072128770 @default.
• W1577654792 cites W2081364921 @default.
• W1577654792 cites W2083563713 @default.
• W1577654792 cites W2097826817 @default.
• W1577654792 cites W2101566669 @default.
• W1577654792 cites W2112749000 @default.
• W1577654792 cites W2115826968 @default.
• W1577654792 cites W2125508519 @default.
• W1577654792 cites W2145539874 @default.
• W1577654792 cites W2146082584 @default.
• W1577654792 cites W2147196015 @default.
• W1577654792 cites W2161498270 @default.
• W1577654792 cites W2171386011 @default.
• W1577654792 doi "https://doi.org/10.1111/j.1600-0404.2011.01599.x" @default.
• W1577654792 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22061179" @default.
• W1577654792 hasPublicationYear "2011" @default.
• W1577654792 type Work @default.
• W1577654792 sameAs 1577654792 @default.
• W1577654792 citedByCount "28" @default.
• W1577654792 countsByYear W15776547922012 @default.
• W1577654792 countsByYear W15776547922013 @default.
• W1577654792 countsByYear W15776547922014 @default.
• W1577654792 countsByYear W15776547922015 @default.
• W1577654792 countsByYear W15776547922016 @default.
• W1577654792 countsByYear W15776547922018 @default.
• W1577654792 countsByYear W15776547922019 @default.
• W1577654792 countsByYear W15776547922020 @default.
• W1577654792 countsByYear W15776547922021 @default.
• W1577654792 crossrefType "journal-article" @default.
• W1577654792 hasAuthorship W1577654792A5058439594 @default.
• W1577654792 hasBestOaLocation W15776547921 @default.
• W1577654792 hasConcept C118552586 @default.
• W1577654792 hasConcept C126322002 @default.
• W1577654792 hasConcept C141071460 @default.
• W1577654792 hasConcept C162156334 @default.
• W1577654792 hasConcept C168563851 @default.
• W1577654792 hasConcept C187212893 @default.
• W1577654792 hasConcept C197934379 @default.
• W1577654792 hasConcept C203092338 @default.
• W1577654792 hasConcept C2775858608 @default.
• W1577654792 hasConcept C2777288759 @default.
• W1577654792 hasConcept C2778186239 @default.
• W1577654792 hasConcept C2780837902 @default.
• W1577654792 hasConcept C42219234 @default.
• W1577654792 hasConcept C535046627 @default.
• W1577654792 hasConcept C71924100 @default.
• W1577654792 hasConceptScore W1577654792C118552586 @default.
• W1577654792 hasConceptScore W1577654792C126322002 @default.
• W1577654792 hasConceptScore W1577654792C141071460 @default.
• W1577654792 hasConceptScore W1577654792C162156334 @default.
• W1577654792 hasConceptScore W1577654792C168563851 @default.
• W1577654792 hasConceptScore W1577654792C187212893 @default.
• W1577654792 hasConceptScore W1577654792C197934379 @default.
• W1577654792 hasConceptScore W1577654792C203092338 @default.
• W1577654792 hasConceptScore W1577654792C2775858608 @default.
• W1577654792 hasConceptScore W1577654792C2777288759 @default.
• W1577654792 hasConceptScore W1577654792C2778186239 @default.
• W1577654792 hasConceptScore W1577654792C2780837902 @default.
• W1577654792 hasConceptScore W1577654792C42219234 @default.
• W1577654792 hasConceptScore W1577654792C535046627 @default.
• W1577654792 hasConceptScore W1577654792C71924100 @default.
• W1577654792 hasLocation W15776547921 @default.
• W1577654792 hasLocation W15776547922 @default.
• W1577654792 hasOpenAccess W1577654792 @default.
• W1577654792 hasPrimaryLocation W15776547921 @default.
• W1577654792 hasRelatedWork W1986636301 @default.
• W1577654792 hasRelatedWork W1992609868 @default.
• W1577654792 hasRelatedWork W2057743042 @default.
• W1577654792 hasRelatedWork W2080090598 @default.
• W1577654792 hasRelatedWork W2104981570 @default.
• W1577654792 hasRelatedWork W2132785864 @default.
• W1577654792 hasRelatedWork W2358624079 @default.
• W1577654792 hasRelatedWork W2618612696 @default.

• next